ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintTitle ChevronIcon Twitter
Coronavirus

Japan seals deal with Pfizer for COVID shots for 72m people

Supplies to be sufficient to vaccinate more than half country's population

The government expects to begin vaccinating people for COVID-19 in late February.   © Reuters

TOKYO (Kyodo) -- The Japanese government has agreed with U.S. pharmaceutical giant Pfizer Inc. to receive a supply of the drugmaker's novel coronavirus vaccine sufficient for 72 million people within this year, the health ministry said Wednesday.

The agreement secures doses for an additional 12 million people after Japan agreed last year with the drugmaker to receive doses for 60 million people, or roughly half its population of 126 million.

The Pfizer vaccine is the only one already under review by the ministry. The vaccine supply is contingent on government approval.

Prime Minister Yoshihide Suga has said his government is preparing vaccinations to start by late February.

Following a resurgence of infections, Suga declared a monthlong state of emergency on Jan. 7 for Tokyo and three neighboring prefectures, later expanding it to another seven of the country's 47 prefectures.

Vaccinations will first be given to medical workers, followed by people aged 65 or older from late March, then people with pre-existing conditions and those caring for the elderly.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends January 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more